The increasing adoption of ALK inhibitor drugs, rapid advancements in the precision oncology market, and rising demand for innovative lung cancer drugs market solutions are transforming the treatment landscape for advanced lung cancers. Metastatic lung adenocarcinoma, a form of non-small cell lung cancer (NSCLC), requires highly targeted and personalized treatment approaches due to its complex...